Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30,957 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Najjar YG, et al. Among authors: lin y, lin h. Clin Cancer Res. 2021 Aug 1;27(15):4195-4204. doi: 10.1158/1078-0432.CCR-20-4301. Epub 2021 Mar 22. Clin Cancer Res. 2021. PMID: 33753453 Free PMC article.
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Tarhini A, et al. Among authors: lin y, lin h. J Immunother Cancer. 2018 Oct 23;6(1):112. doi: 10.1186/s40425-018-0428-5. J Immunother Cancer. 2018. PMID: 30352626 Free PMC article.
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
Andrews LP, Somasundaram A, Moskovitz JM, Szymczak-Workman AL, Liu C, Cillo AR, Lin H, Normolle DP, Moynihan KD, Taniuchi I, Irvine DJ, Kirkwood JM, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Andrews LP, et al. Among authors: lin h. Sci Immunol. 2020 Jul 17;5(49):eabc2728. doi: 10.1126/sciimmunol.abc2728. Sci Immunol. 2020. PMID: 32680952 Free PMC article.
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.
Maguire WF, Schmitz JC, Scemama J, Czambel K, Lin Y, Green AG, Wu S, Lin H, Puhalla S, Rhee J, Stoller R, Tawbi H, Lee JJ, Wright JJ, Beumer JH, Chu E, Appleman LJ; ETCTN-9153 Study Team. Maguire WF, et al. Among authors: lin y, lin h. Cancer Chemother Pharmacol. 2021 Oct;88(4):643-654. doi: 10.1007/s00280-021-04317-y. Epub 2021 Jun 23. Cancer Chemother Pharmacol. 2021. PMID: 34164713 Free PMC article. Clinical Trial.
Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases.
Tang H, Lu Q, Feng S, Xiao Z, Wu W, Chen G, Deng L, Yu T, Wu J, Lin H, Ji B, Lin J, Zhang C, Li L, Liu T, Ouyang Y, Lei K, Chen J, Peng W, Qiu Z, Cai Q, Liang Q, Liu C, Li Y, Zhu L, Zhang Z, Liu X, Lin L, Zheng Z. Tang H, et al. Among authors: lin h. Pharm Biol. 2024 Dec;62(1):472-479. doi: 10.1080/13880209.2024.2350233. Epub 2024 May 20. Pharm Biol. 2024. PMID: 38769628 Review.
Inflammation Triggers Chondrocyte Ferroptosis in TMJOA via HIF-1α/TFRC.
Chen BY, Pathak JL, Lin HY, Guo WQ, Chen WJ, Luo G, Wang LJ, Sun XF, Ding Y, Li J, Diekwisch TGH, Liu C. Chen BY, et al. Among authors: lin hy. J Dent Res. 2024 May 20:220345241242389. doi: 10.1177/00220345241242389. Online ahead of print. J Dent Res. 2024. PMID: 38766865
30,957 results
You have reached the last available page of results. Please see the User Guide for more information.